Abbott Laboratories ABT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABT is a good fit for your portfolio.
News
-
Abbott Laboratories on Pace for Largest Percent Decrease Since October 2023 — Data Talk
-
Abbott Labs' first-quarter results top estimates amid strong medical-device sales
-
Abbott Gets FDA Approval for TriClip Heart Valve Repair System
-
Abbott Laboratories Cartridge Gets FDA Clearance to be Used with Whole Blood
-
Here's what families need to know after a landmark $60 million verdict in baby-formula suit
-
Enfamil maker vows to fight $60 million baby-formula verdict as stock slides
-
Abbott Laboratories On Track for Largest Percent Decrease Since October 2023 — Data Talk
-
Abbott Laboratories says FDA independent panel votes to approve heart device
Trading Information
- Previous Close Price
- $112.41
- Day Range
- $111.55–111.55
- 52-Week Range
- $102.11–114.26
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $195.05 Bil
- Volume/Avg
- 20 / 125
Key Statistics
- Price/Earnings (Normalized)
- 25.32
- Price/Sales
- 4.87
- Dividend Yield (Trailing)
- 1.89%
- Dividend Yield (Forward)
- 1.96%
- Total Yield
- 2.55%
Company Profile
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Large Core
- Total Number of Employees
- 114,000
- Website
- https://www.abbottinvestor.com
Competitors
Valuation
|
Metric
|
ABT
|
BSX
|
MDT
|
|---|---|---|---|
Price/Earnings (Normalized) | 25.32 | 35.57 | 14.64 |
Price/Book Value | 5.05 | 5.54 | 2.03 |
Price/Sales | 4.87 | 7.49 | 3.26 |
Price/Cash Flow | 20.19 | 32.59 | 14.42 |
Price/Earnings
ABT
BSX
MDT
Financial Strength
|
Metric
|
ABT
|
BSX
|
MDT
|
|---|---|---|---|
Quick Ratio | 1.16 | 0.63 | 1.46 |
Current Ratio | 1.64 | 1.32 | 2.30 |
Interest Coverage | 10.86 | 8.41 | 8.86 |
Quick Ratio
ABT
BSX
MDT
Profitability
|
Metric
|
ABT
|
BSX
|
MDT
|
|---|---|---|---|
Return on Assets (Normalized) | 10.63% | 8.92% | 7.75% |
Return on Equity (Normalized) | 20.87% | 16.33% | 13.75% |
Return on Invested Capital (Normalized) | 14.81% | 11.43% | 9.87% |
Return on Assets
ABT
BSX
MDT
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Dhmlmjpj | Vntkrtt | $185.5 Bil | |
SYK
| Stryker Corp | Rtfyylpk | Hng | $128.2 Bil | |
MDT
| Medtronic PLC | Rfmtdlt | Mmnzsyx | $106.7 Bil | |
BSX
| Boston Scientific Corp | Btnjltx | Szpygv | $99.0 Bil | |
DXCM
| DexCom Inc | Scfyyjftpt | Mksq | $53.1 Bil | |
EW
| Edwards Lifesciences Corp | Jswylrrc | Mbcqxr | $52.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Qczqjybvcg | Ylrk | $24.9 Bil | |
ALGN
| Align Technology Inc | Pxqpckjm | Xxnshw | $23.5 Bil | |
PHG
| Koninklijke Philips NV ADR | Nvwlwzdjy | Yypxt | $18.9 Bil | |
PODD
| Insulet Corp | Qxxykpghq | Hvcgxk | $11.7 Bil |